Comparative Pharmacology
Head-to-head clinical analysis: CANTIL versus SOLIFENACIN SUCCINATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANTIL versus SOLIFENACIN SUCCINATE.
CANTIL vs SOLIFENACIN SUCCINATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and gastric acid secretion.
Solifenacin is a competitive muscarinic receptor antagonist. It binds selectively to M3 muscarinic receptors, inhibiting acetylcholine action on smooth muscle of the urinary bladder, reducing detrusor overactivity and increasing bladder capacity.
50 mg orally three times daily, may increase to 100 mg three times daily if needed
5 mg orally once daily, may increase to 10 mg once daily if tolerated.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours; clinically, this supports twice-daily dosing in patients with normal renal function.
Terminal elimination half-life is approximately 45-68 hours (mean ~55 hours) in healthy adults, allowing once-daily dosing.
Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% eliminated renally, with about 30-40% excreted in feces via biliary elimination.
Primarily renal: ~69% as metabolites (including active metabolite 4R-hydroxy solifenacin) and ~7% as unchanged drug. Fecal excretion accounts for ~23% (mainly as metabolites).
Category C
Category A/B
Anticholinergic / Antispasmodic
Anticholinergic